Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

24 sept. 2020 06h00 HE | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics Presents New Data from MOMENTUM Phase 3 Trial with AXS-07 Demonstrating Rapid Onset of Action and Reduced Symptom Recurrence in the Acute Treatment of Migraine

Significantly faster time to pain relief as compared to rizatriptan (p<0.001) Significantly less relapse of migraine pain as compared to rizatriptan (p=0.001) Benefits demonstrated in...
06 avr. 2020 06h00 HE | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics Announces AXS-07 Achieves Both Co-Primary Endpoints and Prevents Migraine Pain Progression in the INTERCEPT Phase 3 Trial in the Early Treatment of Migraine

Achieved freedom from migraine pain in 33% of AXS-07 patients versus 16% for placebo at 2 hours (co-primary endpoint, p=0.002) Prevented progression of migraine pain beyond mild intensity in 74% of...
21 nov. 2019 07h00 HE | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics to Host Investor R&D Call with Key Opinion Leaders Focusing on AXS-07 and the Unmet Needs in the Acute Treatment of Migraine

Company to host conference call on Monday, November 25 at 9:00 AM Eastern NEW YORK, Nov. 21, 2019 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage...